LITESPARK-022 supports belzutifan plus pembrolizumab as an additional adjuvant option after nephrectomy for high-risk clear-cell RCC, not a wholesale replacement for pembrolizumab alone. The regimen improved disease-free survival versus pembrolizumab alone, but overall survival remains unproven and toxicity is meaningfully higher.

Why It Matters To Your Practice

• The FDA approved belzutifan plus pembrolizumab in June 2026 for adults with RCC containing a clear-cell component at intermediate-high or high risk of recurrence after nephrectomy, including eligible patients with no evidence of disease after resection of metastatic lesions.

• In the phase III trial, 1,841 patients received pembrolizumab with either belzutifan or placebo. The hazard ratio for recurrence or death was 0.72, and estimated 24-month disease-free survival was 80.7% versus 73.7%. That is an incremental benefit against active adjuvant therapy, not against observation alone.

Clinical Implications

• Pembrolizumab monotherapy remains a valid choice because KEYNOTE-564 established an overall survival benefit versus placebo, whereas LITESPARK-022 has not shown a statistically significant overall survival advantage for the combination over pembrolizumab alone.

• Treatment selection should weigh recurrence risk, patient preference, and tolerance for added monitoring and adverse effects. Surveillance can still be discussed when adjuvant therapy is declined or when expected harms outweigh expected benefit, but these data should not be extrapolated beyond RCC with a clear-cell component.

Insights

• Mechanistically, belzutifan inhibits HIF-2α, a pathway relevant to many clear-cell RCCs with VHL loss, while pembrolizumab blocks PD-1. That biologic rationale supports combining tumor-pathway inhibition with immune checkpoint blockade, but the precise interaction responsible for the adjuvant benefit has not been established, and no validated biomarker identifies who benefits from a specific HIF-2α and PD-1 interaction.

• Toxicity is a major differentiator. Grade 3 or higher adverse events occurred in 52.1% with belzutifan plus pembrolizumab versus 30.2% with pembrolizumab plus placebo. Anemia and hypoxia are the signature belzutifan risks: hemoglobin decreased from baseline in 95% of combination-treated patients, with grade 3 to 4 decreases in 11%, and hypoxia occurred in 7%, including grade 3 or higher events in 5%. Pre-existing anemia, impaired oxygenation, cardiopulmonary disease, or difficulty attending monitoring visits deserve particular attention before escalation to the combination regimen.

The Bottom Line

• For eligible patients with high-risk clear-cell RCC after nephrectomy, belzutifan plus pembrolizumab offers a disease-free survival gain over pembrolizumab alone, with substantially more toxicity and no confirmed overall survival benefit yet.

• Use it as an escalation option for selected patients, not as the new default for everyone receiving adjuvant therapy.

Please review content for accuracy. You are the final authority.